RxDoctor Payments Data

Mrugendra Patel, MD

Neurology · Chesapeake, VANPI 1710903430

Payments from drug & device makers

$1,832in general payments, 2019–2025

Across 91 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$446
  • Eisai Inc.$252
  • Amgen$127
  • Biogen$119
  • Medtronic$88
  • Lundbeck LLC$71
  • plus $728 from 21 others

What the payments were for

  • Speaking & faculty fees$181%
  • Food & beverage$1,78798%
  • Education$271%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,832 in reported general payments places this provider in the 50th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$73,469
Medicare patients
390
Services billed
1,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aimovig AutoinjectorErenumab-Aooe31$21,606
UbrelvyUbrogepant14$20,364
Emgality PenGalcanezumab-Gnlm14$12,462
Depakote ErDivalproex Sodium12$9,732
DilantinPhenytoin Sodium Extended27$7,186
Divalproex Sodium39$5,470
Levetiracetam150$3,580
Carbamazepine ErCarbamazepine15$3,362
Divalproex Sodium ErDivalproex Sodium32$3,349
Pregabalin96$3,231
Gabapentin318$3,185
Oxcarbazepine47$3,105
CarbatrolCarbamazepine14$2,607
Memantine Hcl93$2,514
Donepezil Hcl196$1,839

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$446$20,36414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 474 neurology providers in Virginia.

Other neurology in Chesapeake

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →